{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:19:02Z","timestamp":1788221942428,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2025.101361","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T15:04:11Z","timestamp":1766934251000},"page":"101361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives"],"prefix":"10.1016","volume":"76","author":[{"given":"Mar\u00eda Luisa","family":"Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.blre.2025.101361_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia \u2013 current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.blre.2025.101361_bb0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17474086.2021.1995347","article-title":"Immune thrombocytopenia","volume":"14","author":"Bussel","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0015","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101361_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2025.101361_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"Kistangari","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2025.101361_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0035","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ajh.24463","article-title":"Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease","volume":"91","author":"Efficace","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0045","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3324\/haematol.2014.106963","article-title":"Health-related quality of life in children with newly diagnosed immune thrombocytopenia","volume":"99","author":"Heitink-Poll\u00e9","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101361_bb0050","first-page":"253","article-title":"Recommendations for the management of acute immune thrombocytopenia in children. A consensus conference from the Italian Association of Pediatric Hematology and Oncology","volume":"22","author":"Russo","year":"2024","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2025.101361_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101300","article-title":"The new era of primary immune thrombocytopenia management in adults: a narrative review of current and emerging treatments","volume":"73","author":"Gonz\u00e1lez-L\u00f3pez","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101361_bb0060","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/ajh.27448","article-title":"2025 update on clinical trials in immune thrombocytopenia","volume":"99","author":"Al-Samkari","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0065","series-title":"Promacta [package insert]","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0070","series-title":"Nplate [package insert]","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0075","series-title":"Doptelet [package insert]","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101361_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed Rep"},{"key":"10.1016\/j.blre.2025.101361_bb0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/hematology.2022000374","article-title":"Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem","volume":"2022","author":"Al-Samkari","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101361_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101361_bb0100","series-title":"Doptelet [summary of product characteristics]","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0105","series-title":"Asahi Kasei Pharma obtains approval for Doptelet\u00ae tablet 20 mg for the additional indication of persistent and chronic immune thrombocytopenia [press release]","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0110","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2014.07.007","article-title":"Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure","volume":"61","author":"Terrault","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2025.101361_bb0115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2025.101361_bb0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101361_bb0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0130","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/jth.14295","article-title":"Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease","volume":"16","author":"Michelson","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101361_bb0135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ejh.14395","article-title":"Avatrombopag for the treatment of immune thrombocytopenia","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.15574","article-title":"Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled phase 1 studies","volume":"183","author":"Kuter","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/08971900221125827","article-title":"Avatrombopag for the treatment of immune thrombocytopenia and periprocedural thrombocytopenia associated with chronic liver disease","volume":"37","author":"Tran","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.blre.2025.101361_bb0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpdd.349","article-title":"Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects","volume":"7","author":"Nomoto","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.blre.2025.101361_bb0160","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.24705","article-title":"Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia","volume":"92","author":"Lambert","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0165","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/ajh.26543","article-title":"Long-term eltrombopag for bone marrow failure depletes iron","volume":"97","author":"Young","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0170","first-page":"139","article-title":"Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey","volume":"37","author":"Koca Yozgat","year":"2020","journal-title":"Turk J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000508599","article-title":"An eltrombopag red (plasma) alert","volume":"144","author":"Al-Samkari","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/16078454.2021.1978689","article-title":"Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)","volume":"26","author":"McDonald","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101361_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2253069","article-title":"Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort","volume":"28","author":"Lucchesi","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101361_bb0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0039-1700512","article-title":"Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment","volume":"46","author":"Al-Samkari","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2025.101361_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0200","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1016\/S2352-3026(25)00107-3","article-title":"Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study","volume":"12","author":"Grace","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Virk","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0210","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.19973","article-title":"Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: a real-world observational study","volume":"206","author":"Wang","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0220","series-title":"Efficacy and safety of oral E5501 plus standard of care for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (amendment 02)","year":"2018"},{"key":"10.1016\/j.blre.2025.101361_bb0225","year":"2018"},{"key":"10.1016\/j.blre.2025.101361_bb0230","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.18908","article-title":"A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP","volume":"202","author":"Tarantino","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0235","series-title":"Avatrombopag for the treatment of thrombocytopenia in pediatric subjects with immune thrombocytopenia for \u22656 months","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102158","article-title":"Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China","volume":"7","author":"Mei","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101361_bb0245","series-title":"Evaluation of avatrombopag for the treatment of thrombocytopenia in Japanese adults with chronic ITP","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12185-025-04001-4","article-title":"A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia","volume":"122","author":"Yamaguchi","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0255","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2024015635","article-title":"Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA","volume":"9","author":"Tarantino","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101361_bb0260","series-title":"An observational, multicenter study to evaluate the use and effectiveness of Doptelet\u00ae in patients with ITP (ADOPT)","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0265","series-title":"Presented at: The Annual Congress of the European Hematology Association","article-title":"Effectiveness and safety of avatrombopag for the treatment of adults with newly diagnosed, persistent, or chronic immune thrombocytopenia: interim results from the phase 4 ADOPT study [poster PS2231]","author":"Ghanima","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0270","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2195016","article-title":"Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia","volume":"34","author":"Jain","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2025.101361_bb0275","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231179856","article-title":"Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study","volume":"14","author":"Oladapo","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0280","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjh.19975","article-title":"Avatrombopag in adults with immune thrombocytopenia: a multicentre real-life observational study in Madrid, Spain (AVAMAD study)","volume":"206","author":"Pascual-Izquierdo","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0285","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/ajh.27498","article-title":"Avatrombopag in immune thrombocytopenia: a real-world study of the Spanish ITP Group (GEPTI)","volume":"99","author":"Pascual-Izquierdo","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0290","series-title":"Presented at: The Annual Congress of the European Hematology Association","article-title":"Effectiveness and safety of avatrombopag for treatment of immune thrombocytopenia in older patients and those with comorbidities or prior TPO-RA exposure: interim results from the phase 4 ADOPT study [poster PS2242]","author":"Mingot-Castellano","year":"2025"},{"key":"10.1016\/j.blre.2025.101361_bb0295","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/bjh.19342","article-title":"Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: a multicentre observational retrospective study in China","volume":"204","author":"Wang","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0300","article-title":"Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data","volume":"12","author":"Liu","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.blre.2025.101361_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101361_bb0310","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bjh.19800","article-title":"Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag\/hetrombopag","volume":"205","author":"Tian","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0315","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.18864","article-title":"Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: a real-world study in China","volume":"202","author":"Cheng","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0320","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2170999","article-title":"European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia","volume":"34","author":"Barlassina","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2025.101361_bb0325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/medicina59040659","article-title":"Sustained remission off-treatment (SROT) of TPO-RAs: the Burgos ten-step eltrombopag tapering scheme","volume":"59","author":"Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.blre.2025.101361_bb0330","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.27131","article-title":"Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial","volume":"99","author":"Cooper","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0335","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101361_bb0340","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.2024025707","article-title":"Long-term follow-up of the STOPAGO study","volume":"145","author":"Cottu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101361_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970978","article-title":"Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: a multicenter, open-label, single-arm trial","volume":"13","author":"Cui","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2025.101361_bb0350","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101361_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102980","article-title":"Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?","volume":"9","author":"Al-Samkari","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101361_bb0365","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0370","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0375","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjh.19797","article-title":"Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: a case series","volume":"206","author":"Galamaga","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0380","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.19861","article-title":"A second chance for avatrombopag in chemotherapy-induced thrombocytopenia","volume":"206","author":"Al-Samkari","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101361_bb0385","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12957-025-03659-8","article-title":"Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors","volume":"23","author":"Hu","year":"2025","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.blre.2025.101361_bb0390","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241304300","article-title":"Efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in children with acute lymphoblastic leukemia: a single-center retrospective study","volume":"15","author":"Yang","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104670","article-title":"Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia","volume":"140","author":"Li","year":"2024","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0400","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231191310","article-title":"Comparison of eltrombopag and avatrombopag in the treatment of refractory\/relapsed aplastic anemia: a single-center retrospective study in China","volume":"14","author":"Zhang","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0405","article-title":"Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101361_bb0410","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2224044","article-title":"Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory\/relapsed\/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial","volume":"55","author":"Wan","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.blre.2025.101361_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1099372","article-title":"Avatrombopag for the treatment of thrombocytopenia in children\u2019s patients following allogeneic hematopoietic stem-cell transplantation: a pilot study","volume":"11","author":"Ruan","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.blre.2025.101361_bb0420","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221127532","article-title":"Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation","volume":"13","author":"Zhou","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101361_bb0425","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101361_bb0430","first-page":"351","article-title":"Uso de los an\u00e1logos de la trombopoyetina en pacientes con trombocitopenia tras CAR-T [abstract PO-380]","volume":"43","author":"P\u00e9rez Rodr\u00edguez","year":"2024","journal-title":"Sangre (Barc)"},{"key":"10.1016\/j.blre.2025.101361_bb0435","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3390\/ijms22094330","article-title":"Role of thrombopoietin receptor agonists in inherited thrombocytopenia","volume":"22","author":"Bastida","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101361_bb0440","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/a-2247-4209","article-title":"Update on the use of thrombopoietin-receptor agonists in pediatrics","volume":"44","author":"Gebetsberger","year":"2024","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.blre.2025.101361_bb0445","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"Pecci","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101361_bb0450","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101361_bb0455","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3324\/haematol.2019.223966","article-title":"Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial","volume":"105","author":"Zaninetti","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101361_bb0460","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/09537104.2022.2096211","article-title":"Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure","volume":"33","author":"Arif","year":"2022","journal-title":"Platelets"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:10:28Z","timestamp":1788221428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":92,"alternative-id":["S0268960X25001067"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101361","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101361"}}